Today, Benzinga 's options scanner spotted 15 uncommon options trades for Cassava Sciences. This isn't normal. The overall ...

An Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Oral Simufilam in On-going Phase 3 Trials. The DSMB Recommended Both Phase 3 Trials ...

26, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (“Cassava” or the “Company ... Annual Report on Form 10-K for the year ended December 31, 2023, in our Quarterly Report on Form ...

Cassava Sciences, Inc. (NASDAQ:SAVA) shares are trading higher ... Alzheimer's disease who received simufilam continuously for 24 months. “We’re fighting Alzheimer’s disease by testing ...

Cassava Sciences, Inc. SAVA on Tuesday announced the completion of an interim safety review of its Alzheimer's drug candidate, simufilam. Here’s what you need to know. Cassava Sciences reported ...

Cassava Sciences, Inc. (Nasdaq: ADAS-Cog Scores Were Stable in a Group of Patients with Mild Alzheimer’s Who Received Drug Candidate Simufilam Continuously, Baseline to Month 24.Mild Alzheimer ...

ByInvesting.com • Mar 14, 2024 ROSEN, A LEADING NATIONAL FIRM, Encourages Cassava Sciences, Inc. Investors to Secure ... Baseline to Month 24.Mild Alzheimer's Patients Who ...

26, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (“Cassava&CloseCurlyDoubleQuote ... in our Annual Report on Form 10-K for the year ended December 31, 2023, in our Quarterly Report on Form 10-Q for ...

Cassava Sciences, Inc. ("Cassava" or the "Company") (Nasdaq: SAVA), a biotechnology company focused on Alzheimer's disease, today announced that it has ...